Emerging treatment options for B-cell lymphomas

Area of Science:

• Oncology
• Hematology
• Immunotherapy

Background:

• Targeted therapy for B-cell lymphomas is evolving beyond traditional anti-CD20 monoclonal antibodies.
• Numerous novel therapeutic agents are currently in development for B-cell malignancies.

Purpose of the Study:

• To review emerging targeted therapies for B-cell lymphomas.
• To discuss novel agents including immunoconjugates, kinase inhibitors, apoptosis modulators, immunomodulators, and immune checkpoint inhibitors.

Main Methods:

• Review of novel therapeutic agents presented at the NCCN 20th Annual Conference.
• Categorization of therapies based on their mechanism of action (e.g., targeting tumor cells, microenvironment, or immune modulation).

Main Results:

• Several novel therapeutic classes are under investigation, including immunoconjugates, Bruton's tyrosine kinase (BTK) inhibitors (e.g., ibrutinib), apoptosis modulators (e.g., venetoclax), immunomodulators (e.g., lenalidomide), and immune checkpoint inhibitors (e.g., nivolumab).
• These agents represent a significant expansion of treatment options for B-cell lymphomas.

Conclusions:

• Emerging targeted therapies offer new strategies to improve outcomes in B-cell lymphomas.
• Therapeutic approaches focus on direct tumor cell targeting or modulating the tumor microenvironment and immune response.